Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

(2022) Peter B. Gilbert et al.   SCIENCE

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

(2022) Sarah Frey et al.   Lancet Rheumatology

EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update

(2022) Robert B M Landewé et al.   ANNALS OF THE RHEUMATIC DISEASES

Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine

(2022) Ria Lassaunière et al.   JAMA Network Open

Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease

(2022) Rebecca H Haberman et al.   Lancet Rheumatology

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

(2022) Laura Boekel et al.   Lancet Rheumatology

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study

(2022) Luuk Wieske et al.   Lancet Rheumatology

Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis

(2022) Jessica Widdifield et al.   Lancet Rheumatology

SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease

(2021) Kristin M D’Silva et al.   ANNALS OF THE RHEUMATIC DISEASES

SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases

(2021) David Simon et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

(2021) Ulf M Geisen et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2

(2021) Parakkal Deepak et al.   ANNALS OF INTERNAL MEDICINE

Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases

(2021) Claire Cook et al.   ANNALS OF THE RHEUMATIC DISEASES

High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases

(2021) Jake A Ruddy et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

(2021) Rebecca H Haberman et al.   ANNALS OF THE RHEUMATIC DISEASES

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

(2021) Amarendra Pegu et al.   SCIENCE

Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort

(2021) Amit Saxena et al.   Lancet Rheumatology

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

(2021) Laura Boekel et al.   Lancet Rheumatology

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study

(2021) Matthias B Moor et al.   Lancet Rheumatology

Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease

(2021) David Simon et al.   ANNALS OF THE RHEUMATIC DISEASES

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

(2021) Shuo Feng et al.   NATURE MEDICINE

Impact of cytokine inhibitor therapy on the prevalence, seroconversion rate and longevity of the humoral immune response against SARS‐CoV ‐2 in an unvaccinated cohort

(2021) David Simon et al.   Arthritis & Rheumatology

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses

(2021) Filippo Fagni et al.   Lancet Rheumatology

Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York

(2020) Rebecca Haberman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion

(2020) David Simon et al.   Nature Communications

COVID‐19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes

(2020) Rebecca H. Haberman et al.   Arthritis & Rheumatology